{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T01:18:41Z","timestamp":1762046321271,"version":"build-2065373602"},"reference-count":25,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,20]],"date-time":"2022-02-20T00:00:00Z","timestamp":1645315200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007054","name":"Meso Scale Diagnostics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Public Health"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.jiph.2022.02.009","type":"journal-article","created":{"date-parts":[[2022,2,22]],"date-time":"2022-02-22T18:09:51Z","timestamp":1645553391000},"page":"486-490","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["In-vitro activity of ceftolozane\/tazobactam against recent clinical bacterial isolates from two Saudi Arabian hospitals"],"prefix":"10.1016","volume":"15","author":[{"given":"Nezar M.","family":"Bahabri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maha Mahmoud","family":"Al-Alawi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed O.","family":"Qutub","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wail A.","family":"Tashkandi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raha","family":"AlTurki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Safiah Saad","family":"Janah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heidi Essam","family":"Ali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Albandari F.","family":"Almutairi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sherif","family":"Khalil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jiph.2022.02.009_bib1","unstructured":"World Health Organization (WHO). Antimicrobial resistance: key facts Web site. [Internet]. World Heatlh Organization, 2018. p. 1\u20137. Available from: \u3008http:\/\/www.who.int\/en\/news-room\/fact-sheets\/detail\/antimicrobial-resistance\u3009."},{"key":"10.1016\/j.jiph.2022.02.009_bib2","unstructured":"The AMR Industry Alliance. Declaration by the Pharmaceutical, Biotechnology and Diagnostics Industries on Combating Antimicrobial Resistance [Internet], 2016. p. 7. Available from: \u3008https:\/\/www.amrindustryalliance.org\/amr-industry-alliance-declaration\/\u3009."},{"issue":"9981","key":"10.1016\/j.jiph.2022.02.009_bib3","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(14)62220-0","article-title":"Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI)","volume":"385","author":"Wagenlehner","year":"2015","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.jiph.2022.02.009_bib4","first-page":"1","article-title":"Activity of ceftolozane-tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae Isolates collected from respiratory tract specimens of hospitalized patients in the United States during 2013 to 2015","volume":"62","author":"Castanheira","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"10.1016\/j.jiph.2022.02.009_bib5","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1128\/CMR.00043-12","article-title":"Adaptive and mutational resistance: role of porins and efflux pumps in drug resistance","volume":"25","author":"Fernandez","year":"2012","journal-title":"Clin Microbiol Rev"},{"issue":"1","key":"10.1016\/j.jiph.2022.02.009_bib6","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.biotechadv.2018.11.013","article-title":"Antibiotic resistance in Pseudomonas aeruginosa: mechanisms and alternative therapeutic strategies","volume":"37","author":"Pang","year":"2019","journal-title":"Biotechnol Adv"},{"issue":"2","key":"10.1016\/j.jiph.2022.02.009_bib7","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.bjid.2020.04.004","article-title":"Evaluation of in vitro activity of ceftolozane\u2013tazobactam against recent clinical bacterial isolates from Brazil \u2013 the EM200 study","volume":"24","author":"Tuon","year":"2020","journal-title":"Braz J Infect Dis"},{"issue":"9","key":"10.1016\/j.jiph.2022.02.009_bib8","doi-asserted-by":"crossref","first-page":"935","DOI":"10.15537\/smj.2016.9.16139","article-title":"Antimicrobial resistance in Saudi Arabia. An urgent call for an immediate action","volume":"37","author":"Zowawi","year":"2016","journal-title":"Saudi Med J"},{"key":"10.1016\/j.jiph.2022.02.009_bib9","unstructured":"Highlights of Prescribing Information \u2013 Zerbaxa, 2019."},{"key":"10.1016\/j.jiph.2022.02.009_bib10","unstructured":"EMA , Zerbaxa. 2020."},{"issue":"1","key":"10.1016\/j.jiph.2022.02.009_bib11","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s40265-013-0168-2","article-title":"Ceftolozane\/Tazobactam: a novel cephalosporin\/\u03b2-lactamase inhibitor combination with activity against multidrug-resistant gram-negative Bacilli","volume":"74","author":"Zhanel","year":"2014","journal-title":"Drugs"},{"issue":"11","key":"10.1016\/j.jiph.2022.02.009_bib12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ofid\/ofy280","article-title":"Ceftolozane-tazobactam for the treatment of multidrug-resistant pseudomonas aeruginosa infections: a multicenter study","volume":"5","author":"Gallagher","year":"2018","journal-title":"Open Forum Infect Dis"},{"issue":"11","key":"10.1016\/j.jiph.2022.02.009_bib13","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1080\/14656566.2021.1915286","article-title":"What place does ceftolozane\/tazobactam have in the treatment of complicated urinary-tract infections?","volume":"22","author":"Murri","year":"2021","journal-title":"Expert Opin Pharm"},{"key":"10.1016\/j.jiph.2022.02.009_bib14","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.2147\/IDR.S180905","article-title":"Ceftolozane\/tazobactam for the treatment of complicated intra-abdominal and urinary tract infections: current perspectives and place in therapy","volume":"12","author":"Escol\u00e0-Verg\u00e9","year":"2019","journal-title":"Infect Drug Resist"},{"key":"10.1016\/j.jiph.2022.02.009_bib15","first-page":"1","article-title":"Experience with ceftolozane-tazobactam for the treatment of serious Pseudomonas aeruginosa infections in Saudi Tertiary Care Center","volume":"13","author":"Bosaeed","year":"2020","journal-title":"Infect Dis Res Treat"},{"key":"10.1016\/j.jiph.2022.02.009_bib16","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ijid.2017.06.007","article-title":"Comparison of antimicrobial activity between ceftolozane\u2013tazobactam and ceftazidime\u2013avibactam against multidrug-resistant isolates of Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa","volume":"62","author":"Alatoom","year":"2017","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.jiph.2022.02.009_bib17","unstructured":"Clinical Laboratory Standards Institute (CLSI). Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standards -Tenth Edition. CLSI document M07-A10 [Internet], 2015. Available from: http:\/\/link.springer.com\/10.1007\/s00259\u2013009-1334\u20133."},{"key":"10.1016\/j.jiph.2022.02.009_bib18","unstructured":"Clinical Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing \u2013 Twenty-Seventh Informational Supplement. CLSI Document M100S, 2017."},{"key":"10.1016\/j.jiph.2022.02.009_bib19","unstructured":"EUCAST. Clinical Breakpoints and Guidance [Internet]. European Society of Clinical Microbiology and Infectious Disease, 2020. Available from: \u3008http:\/\/www.eucast.org\/clinical_breakpoints\/\u3009."},{"key":"10.1016\/j.jiph.2022.02.009_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2016\/4065603","article-title":"Multidrug resistant and extensively drug resistant bacteria: a study","volume":"2016","author":"Basak","year":"2016","journal-title":"J Pathog"},{"issue":"39","key":"10.1016\/j.jiph.2022.02.009_bib21","first-page":"657","article-title":"Susceptible, intermediate, and resistant \u2013 the intensity of antibiotic action","volume":"105","author":"Rodloff","year":"2008","journal-title":"Dtsch Aerzteblatt Online"},{"issue":"7","key":"10.1016\/j.jiph.2022.02.009_bib22","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1016\/j.clinthera.2015.05.501","article-title":"Susceptibility profile of ceftolozane\/tazobactam and other parenteral antimicrobials against Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa from US hospitals","volume":"37","author":"Sutherland","year":"2015","journal-title":"Clin Ther"},{"issue":"12","key":"10.1016\/j.jiph.2022.02.009_bib23","doi-asserted-by":"crossref","first-page":"6305","DOI":"10.1128\/AAC.01802-13","article-title":"Antimicrobial activity of ceftolozane-tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa with various resistance patterns isolated in U.S. hospitals (2011-2012)","volume":"57","author":"Farrell","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"10.1016\/j.jiph.2022.02.009_bib24","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.ijantimicag.2017.06.024","article-title":"In-vitro activity of ceftolozane\/tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae isolates recovered from hospitalized patients in Germany","volume":"51","author":"Seifert","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jiph.2022.02.009_bib25","unstructured":"S. Lob, K. Kazmierczak, I. Alekseeva, K. Young, M. Motyl, D. Sahm, Activity of Ceftolozane \/ tazobactam and Imipenem \/ Relebactam Against Clinical Enterobacteriaceae Isolates Collected in the Middle East \u2013 SMART 2016\u20132018 [Internet], 2019. p. 2019. Available from: \u3008https:\/\/www.ihma.com\/app\/uploads\/Merck_P106_NPE-ME-C-T-IMI-REL_GCCMID-2019_FINAL.pdf\u3009."}],"container-title":["Journal of Infection and Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1876034122000429?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1876034122000429?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T15:15:00Z","timestamp":1761750900000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1876034122000429"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["S1876034122000429"],"URL":"https:\/\/doi.org\/10.1016\/j.jiph.2022.02.009","relation":{},"ISSN":["1876-0341"],"issn-type":[{"type":"print","value":"1876-0341"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In-vitro activity of ceftolozane\/tazobactam against recent clinical bacterial isolates from two Saudi Arabian hospitals","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Public Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jiph.2022.02.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd on behalf of King Saud Bin Abdulaziz University for Health Sciences.","name":"copyright","label":"Copyright"}]}}